• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Baxter International Inc. (BAX)

    -NYSE
    74.48 0.41(0.55%) Dec 19, 4:02PM EST
    |After Hours : 74.48 Down 0.00 (0.00%) Dec 19, 6:51PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Baxter International Inc.
    One Baxter Parkway
    Deerfield, IL 60015
    United States - Map
    Phone: 224-948-2000
    Fax: 224-948-1813
    Website: http://www.baxter.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Medical Instruments & Supplies
    Full Time Employees:61,000

    Business Summary 

    Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Baxter International Inc.

    Corporate Governance 
    Baxter International Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 9. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 10; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Robert L. Parkinson Jr., 63
    Chairman, Chief Exec. Officer and Pres
    4.23M28.84M
    Mr. Robert J. Hombach , 48
    Chief Financial Officer and Corp. VP
    1.63M1.10M
    Mr. Ludwig N. Hantson Ph.D., 51
    Corp. VP and Pres of BioScience
    1.88M0.00
    Mr. Jean-Luc Butel , 57
    Corp. VP and Pres of International
    1.76M0.00
    Mr. Sebastian J. Bufalino , 53
    Principal Accounting Officer, Corp. VP and Controller
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders